Once-weekly high-dose Kyprolis led to higher response rates and longer remissions in re­lapsed / refractory myeloma patients than twice-weekly, lower-dose Kyprolis (car­filz­o­mib), interim results of the Phase 3 "ARROW" clinical trial show.

Dr. Maria-Victoria Mateos presented the trial results earlier this month at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, and also last weekend at the 2018 congress of the European Hematology Association, held in Stockholm. In addi­tion, the trial results were recently published in a medical journal (reference).

The over­all response rate to the two-drug, …